Skip to main content
SpringerLink
Log in

Prophylaxis for Opportunistic Infections in AIDS: Is it Cost Effective?

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Freedberg KA, Palliel AD. Cost effectiveness of prophylaxis for opportunistic infections in AIDS: an overview and methodological discussion. Pharmacoeconomics 1998 Aug; 14 (2): 165–74

    Article  PubMed  CAS  Google Scholar 

  2. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828–33

    Article  PubMed  CAS  Google Scholar 

  3. Powderly WG, Finkelstein OM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332: 700–5

    Article  PubMed  CAS  Google Scholar 

  4. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334: 1491–7

    Article  PubMed  CAS  Google Scholar 

  5. Brosgart CL, Louis TA, Hillman DW, et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals: Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 1998; 12 (3): 269–77

    Article  PubMed  CAS  Google Scholar 

  6. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279: 130–6

    Article  PubMed  CAS  Google Scholar 

  7. Freedberg KA, Tosteson ANA, Cohen CJ, et al. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/111: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991; 4: 521–31

    PubMed  CAS  Google Scholar 

  8. Freedberg KA, Hardy WD, Holzman RS, et al. Validating literature-based models with direct clinical trials results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Making 1996; 16: 29–35

    Article  PubMed  CAS  Google Scholar 

  9. Moore RM, Chaisson RE. Cost-effectiveness analysis for Mycobacterium avium complex disease. Am J Med 1997; 102: 50–5

    Article  Google Scholar 

  10. Freedberg KA, Cohen CJ, Barber TW, et al. Preventing Mycobacterium avium complex infection in patients with AIDS: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1997; 15: 275–82

    Article  CAS  Google Scholar 

  11. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of preventing fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17: 373–81

    Article  PubMed  CAS  Google Scholar 

  12. Moore RD, Chaisson RE. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. J Acquir Immune Defic Syndr 1997; 16: 15–21

    Article  CAS  Google Scholar 

  13. PaItiel AD, Freedberg KA. Cost-effectiveness of preventing CMV disease in AIDS patients. Interfaces. In press

  14. Rose DN, Sacks HS, Lan V. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase cRain reaction testing. AIDS 1997; 11: 883–7

    Article  PubMed  CAS  Google Scholar 

  15. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am J Med 1993; 942: 160–8

    Article  Google Scholar 

  16. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Preface to the 1997 USPHS/IDS guidelines for prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1997; 25 Suppl. 3: S299–312

    Article  Google Scholar 

  17. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago: 184

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prophylaxis for Opportunistic Infections in AIDS: Is it Cost Effective?. Drugs Ther. Perspect 13, 13–16 (1999). https://doi.org/10.2165/00042310-199913060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913060-00005

Keywords

Search

Navigation